UNIGE document Scientific Article
previous document  unige:37150  next document
add to browser collection

The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT.

Marek, A
Stern, M
Güngör, T
Gerber, B
Kühne, T
show hidden authors show all authors [1 - 15]
Published in Bone marrow transplantation. 2014, vol. 49, no. 1, p. 55-61
Abstract Several T-cell depletion (TCD) techniques are used for haploidentical hematopoietic SCT (HSCT), but direct comparisons are rare. We therefore studied the effect of in vitro TCD with graft engineering (CD34 selection or CD3/CD19 depletion, 74%) or in vivo TCD using alemtuzumab (26%) on outcome, immune reconstitution and infections after haploidentical HSCT. We performed a retrospective multicenter analysis of 72 haploidentical HSCT in Switzerland. Sixty-seven patients (93%) had neutrophil engraftment. The 1-year OS, TRM and relapse incidence were 48 (36-60)%, 20 (11-33)% and 42 (31-57)%, respectively, without differences among the TCD groups. In vivo TCD caused more profound lymphocyte suppression early after HSCT, whereas immune recovery beyond the second month was comparable between the two groups. Despite anti-infective prophylaxis, most patients experienced post-transplant infectious complications (94%). Patients with in vivo TCD had a higher incidence of CMV reactivations (54% vs 28%, P=0.015), but this did not result in a higher TRM. In conclusion, TCD by graft engineering or alemtuzumab are equally effective for haploidentical HSCT.
PMID: 24037023
Full text
Article (Published version) (385 Kb) - public document Free access
Research group Oncologie et hématologie pédiatrique (907)
(ISO format)
MAREK, A et al. The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. In: Bone marrow transplantation, 2014, vol. 49, n° 1, p. 55-61. doi: 10.1038/bmt.2013.132 https://archive-ouverte.unige.ch/unige:37150

524 hits



Deposited on : 2014-06-04

Export document
Format :
Citation style :